Treatment‐resistant bullous pemphigoid occurring under antitumour necrosis factor‐α agent therapy in a patient with ulcerative colitis: a case report

2020 ◽  
Vol 34 (7) ◽  
Author(s):  
T. Li ◽  
W. Zhou ◽  
W. Wu ◽  
Y. Zhong ◽  
B. Guan ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Case Report ◽  
Bullous Pemphigoid ◽  
Treatment Resistant ◽  
Factor Α ◽  
Necrosis Factor

Bullous pemphigoid associated with ulcerative colitis in a young child: A case report

2020 ◽  
Vol 33 (6) ◽  
Author(s):  
Yang Wang ◽  
Yuanyuan Xiao ◽  
Yunzhu Li ◽  
Libing Fu ◽  
Feihong Yu ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Case Report ◽  
Young Child ◽  
Bullous Pemphigoid

Mo1860 - High Fecal and Serum Tumor Necrosis Factor-α Levels are Associated with Non-Response to Infliximab in Patients with Ulcerative Colitis

2018 ◽  
Vol 154 (6) ◽  
pp. S-829
Author(s):  
Hadar Meringer-Milwidsky ◽  
Nitsan Maharshak ◽  
Yulia Ron ◽  
Henit A. Yanai ◽  
Sarit Cohen-Kedar ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Factor Α ◽  
Necrosis Factor ◽  
Serum Tumor Necrosis

scholarly journals Association Between Platelet Count and Mucosal Healing in Japanese Patients With Ulcerative Colitis: Cross-Sectional Study

2020 ◽  
Author(s):  
Shinya Furukawa ◽  
Sen Yagi ◽  
Kana Shiraishi ◽  
Kenichirou Mori ◽  
Tomoyuki Ninomiya ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Platelet Count ◽  
Japanese Patients ◽  
Cross Sectional Study ◽  
Mucosal Healing ◽  
Confounding Factors ◽  
Cross Sectional ◽  
Factor Α ◽  
Very High ◽  
Necrosis Factor

Abstract Background: Mucosal healing (MH) has been indicated as the therapeutic goal for ulcerative colitis (UC). Platelet count is known as an inflammation evaluation. However, the association between platelet count and MH among patients with UC is still scarce. We therefore assessed this issue among Japanese patients with UC.Methods: The study subjects consisted of 345 Japanese patients with UC. Platelet count was divided into quartiles on the basis of the distribution of all study subjects (low, moderate, high, and very high). Several endoscope specialists were responsible for evaluating MH and partial MH, which was defined as a Mayo endoscopic subscore of 0 and 0-1, respectively. Estimations of crude odds ratios (ORs) and their 95% confidence intervals (CIs) for partial MH and MH in relation to platelet count were performed using logistic regression analysis. Age, sex, CRP, steroid use, and anti-Tumor necrosis factor α (TNFα) preparation were selected a priori as potential confounding factors.Results: The percentage of partial MH and MH were 63.2 and 26.1%, respectively. Moderate and very high was independently inversely associated with partial MH (moderate: OR 0.40 [95%CI: 0.19-0.810], very high: OR 0.37 [95%CI: 0.17-0.77], p for trend= 0.034). Similarly, moderate, high, and very high were independently inversely associated with MH (moderate: OR 0.37 [95% CI: 0.18-0.73], high: OR 0.41 [95% CI: 0.19-0.83], and very high: OR 0.45 [95% CI: 0.21-0.94], p for trend = 0.033) after adjustment for confounding factors.Conclusions: Among patients with UC, platelet count was independently inversely associated with MH.

scholarly journals Rapid fecal calprotectin testing predicts mucosal healing better than C-reactive protein and serum tumor necrosis factor α in patients with ulcerative colitis

2015 ◽  
Vol 53 (3) ◽  
pp. 253-260
Author(s):  
T. Voiosu ◽  
Andreea Benguş ◽  
P. Bălănescu ◽  
Roxana Dinu ◽  
A. Voiosu ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Fecal Calprotectin ◽  
Mucosal Healing ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Factor Α ◽  
Necrosis Factor

AbstractBackground and Aims. Serum and fecal biomarkers have been used as noninvasive methods for assessing disease activity in ulcerative colitis. C-reactive protein, serum tumor necrosis factor-α and fecal calprotectin are among the most promising such biomarkers. However, their role in the management of ulcerative colitis patients remains to be clarified. We aimed to evaluate the accuracy of C-reactive protein, fecal calprotectin and tumor necrosis factor-α in detecting clinical and endoscopic activity and predicting disease outcome.Methods. A cohort of ulcerative colitis patients was prospectively evaluated for clinical and endoscopic disease activity using the Mayo score. Serum C-reactive protein and tumor necrosis factor-α levels were measured and a point-of-care method was used for determining Calprotectin levels.Results. Fifty-three patients with ulcerative colitis were followed for a median of 12 months. Fecal calprotectin and C-reactive protein levels were significantly higher in patients with clinically active disease at baseline, but only calprotectin levels correlated with endoscopic activity. Calprotectin values over 300 μg/g had 60% sensitivity and 90% specificity for detecting active endoscopic disease and 61% sensitivity and 89% specificity for predicting mucosal healing.Conclusion. Rapid calprotectin testing is a better predictor of mucosal healing than serum biomarkers and it could improve the management of ulcerative colitis patients by decreasing the need for invasive investigations.

Normalization of mucosal tumor necrosis factor-α: A new criterion for discontinuing infliximab therapy in ulcerative colitis

Cytokine ◽  
2016 ◽  
Vol 79 ◽  
pp. 90-95 ◽  
Author(s):  
Trine Olsen ◽  
Renathe Rismo ◽  
Mona Dixon Gundersen ◽  
Eyvind J. Paulssen ◽  
Knut Johnsen ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Infliximab Therapy ◽  
Factor Α ◽  
New Criterion ◽  
Necrosis Factor

scholarly journals Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis

2015 ◽  
Vol 21 (11) ◽  
pp. 3282-3290 ◽  
Author(s):  
Enayatullah Baki ◽  
Philipp Zwickel ◽  
Anna Zawierucha ◽  
Robert Ehehalt ◽  
Daniel Gotthardt ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Real Life ◽  
Ambulatory Treatment ◽  
Factor Α ◽  
Necrosis Factor
Sign in / Sign up

Export Citation Format

Share Document